ES2294793T3 - Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico. - Google Patents

Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico. Download PDF

Info

Publication number
ES2294793T3
ES2294793T3 ES97905226T ES97905226T ES2294793T3 ES 2294793 T3 ES2294793 T3 ES 2294793T3 ES 97905226 T ES97905226 T ES 97905226T ES 97905226 T ES97905226 T ES 97905226T ES 2294793 T3 ES2294793 T3 ES 2294793T3
Authority
ES
Spain
Prior art keywords
antibody
therapeutic
use according
binding
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97905226T
Other languages
English (en)
Spanish (es)
Inventor
Herman Waldmann
Lisa Kim Gilliland
Masahide Tone
Mark Raymond Frewin
Louise Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Application granted granted Critical
Publication of ES2294793T3 publication Critical patent/ES2294793T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES97905226T 1996-02-20 1997-02-20 Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico. Expired - Lifetime ES2294793T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants
GB9603507 1996-02-20

Publications (1)

Publication Number Publication Date
ES2294793T3 true ES2294793T3 (es) 2008-04-01

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97905226T Expired - Lifetime ES2294793T3 (es) 1996-02-20 1997-02-20 Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico.

Country Status (11)

Country Link
US (2) US20020048578A1 (enExample)
EP (1) EP0970127B1 (enExample)
JP (1) JP4574750B2 (enExample)
AT (1) ATE373016T1 (enExample)
AU (1) AU723366B2 (enExample)
CA (1) CA2246715C (enExample)
DE (1) DE69738138T2 (enExample)
ES (1) ES2294793T3 (enExample)
GB (1) GB9603507D0 (enExample)
NZ (1) NZ331299A (enExample)
WO (1) WO1997031024A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0859841B1 (en) * 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
KR20060002896A (ko) * 2003-03-31 2006-01-09 기린 비루 가부시키가이샤 항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
NZ550815A (en) * 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
AU2006226192A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100197896A1 (en) * 2007-05-16 2010-08-05 Leung Shui-On Functional humanization of complementarity determining regions (cdrs)
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9494597B2 (en) * 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
EP3962926A4 (en) 2019-04-30 2022-11-23 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
KR100264218B1 (ko) * 1991-10-15 2000-08-16 그레이엄 브레레톤 관절의 T-세포 매개 염증의 치료용 CDw52-특이 항체
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
US8440190B2 (en) 2013-05-14
US20020048578A1 (en) 2002-04-25
AU723366B2 (en) 2000-08-24
EP0970127B1 (en) 2007-09-12
JP4574750B2 (ja) 2010-11-04
ATE373016T1 (de) 2007-09-15
CA2246715C (en) 2008-08-05
GB9603507D0 (en) 1996-04-17
US20060018898A1 (en) 2006-01-26
CA2246715A1 (en) 1997-08-28
WO1997031024A1 (en) 1997-08-28
EP0970127A1 (en) 2000-01-12
JP2000506723A (ja) 2000-06-06
DE69738138T2 (de) 2008-06-05
NZ331299A (en) 2000-05-26
AU1885197A (en) 1997-09-10
DE69738138D1 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
EP0970127B1 (en) Induction of immunological tolerance to a therapeutic antibody using variants of the said therapeutic antibody
ES2199216T3 (es) Produccion de anticuerpos.
ES2296839T3 (es) Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
US7524498B2 (en) Human immunomodulatory monoclonal antibodies for the treatment of cancer
JP4214173B2 (ja) 寛容原性融合タンパク質による寛容性の誘発
US6294654B1 (en) Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region
ES2368387T5 (es) Anticuerpos terapéuticos y que inducen tolerancia
US8187600B2 (en) Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses
ES2277336T3 (es) Antagonistas de il-5 recombinantes utiles en el tratamiento de enfermadades mediadas por il-5.
JPH08511421A (ja) 人化抗体
ES2307301T3 (es) ANTICUERPO LO-CD2a Y USOS DEL MISMO PARA INHIBIR LA ACTIVACION Y PROLIFERACION DE CELULAS T.
BG62656B1 (bg) Рекомбинантни антитела за хуманната медицина
HU228159B1 (en) Antibodies to human il-1beta
US7635476B2 (en) Anti-hepatitis a virus antibodies
ES2234099T3 (es) Anticuerpos monoclanales humanizados anti-alfa beta 3.
AU2002225230A1 (en) Polypeptides capable of binding to CD64 and comprising one or more heterologous T cell epitopes, and their uses
Zanetti et al. Idiotype Vaccines by Antibody Engineering: Structural and Functional Considerations
Zanetti et al. Idiotype Vaccines by Antibody Engineering: Structural and Functional
RO116809B1 (ro) Anticorp recombinant, monoclonal, compozitie farmaceutica si metoda de tratament cu aceasta